Torre L, Vazquez J A, Blázquez E
Horm Res. 1986;23(3):159-66. doi: 10.1159/000180312.
The secretory response and immunoreactive heterogeneity of glucagon was investigated in a patient with glucagonoma syndrome. After glucose administration, abnormal insulin release accompanied by glucose intolerance were observed, whereas the high glucagon circulating levels were only partially blocked after glucose or somatostatin infusion. Chromatographic fractionation of plasma samples, before and after arginine administration showed that most of the immunoreactivity eluted as true glucagon. Furthermore, when aliquots of the tumor extracts were fractionated by column chromatography or by polyacrylamide gel electrophoresis, most of the immunoreactivity eluted in the 3,500 molecular weight peak. In contrast with previous reports, our results indicate that neoplasia A cells can also manufacture and release into the bloodstream great amounts of genuine glucagon rather than larger glucagon immunoreactive forms. In spite of such findings, in this patient neither diabetes nor hyperglycemia were present.
在一名患有胰高血糖素瘤综合征的患者中，对胰高血糖素的分泌反应和免疫反应异质性进行了研究。给予葡萄糖后，观察到异常的胰岛素释放并伴有葡萄糖不耐受，而在输注葡萄糖或生长抑素后，循环中高水平的胰高血糖素仅被部分阻断。精氨酸给药前后血浆样本的色谱分离显示，大部分免疫反应性以真正的胰高血糖素形式洗脱。此外，当肿瘤提取物的等分试样通过柱色谱或聚丙烯酰胺凝胶电泳进行分离时，大部分免疫反应性在分子量为3500的峰中洗脱。与先前的报道相反，我们的结果表明，肿瘤A细胞也可以制造并释放大量真正的胰高血糖素进入血液，而不是更大的具有胰高血糖素免疫反应性的形式。尽管有这些发现，但该患者既没有糖尿病也没有高血糖。
